SSII SS Innovations International, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1676163 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY27.3%
TTM net income YoY15.5%
TTM EPS YoY-16.7%
Revenue 3-yr CAGR104.7%
Net income 3-yr CAGR—
Margins
Gross margin47.7%
Operating margin-27.7%
Net margin-31.5%
FCF margin—
EBITDA margin-24.8%
Returns
ROE-32.3%
ROA-17.4%
ROIC (approx.)-28.4%
Asset turnover0.55x
Leverage & solvency
Liabilities / assets48.3%
Debt / equity0.03x
Current ratio2.10x
Interest coverage-8.95x
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio-0.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $42.48M | $20.65M |
| Cost of revenue | $22.94M | $12.20M |
| Gross profit | $19.54M | $8.45M |
| R&D expense | $3.69M | $2.49M |
| SG&A expense | $14.85M | $10.16M |
| Operating income | -$8.19M | -$18.98M |
| Interest expense | $1.11M | $973,235 |
| Pretax income | -$8.16M | -$19.15M |
| Income tax | $3.97M | — |
| Net income | -$12.13M | -$19.15M |
| EBITDA | -$7.12M | -$18.54M |
| EPS (basic) | -0.06 | -0.11 |
| EPS (diluted) | -0.06 | -0.11 |
| Weighted avg. shares (diluted) | 198.70M | 181.20M |
| Banking | ||
| Net interest income | $497,549 | $335,222 |
| Balance sheet | ||
| Cash & equivalents | $3.21M | $6.62M |
| Receivables | $12.40M | $4.47M |
| Inventory | $17.06M | $10.21M |
| Current assets | $48.77M | $27.42M |
| PP&E, net | $9.10M | $5.39M |
| Total assets | $74.23M | $42.39M |
| Current liabilities | $26.24M | $21.33M |
| Short-term debt | $11.44M | — |
| Total liabilities | $36.01M | $28.93M |
| Shareholders' equity | $38.22M | $13.46M |
| Shares outstanding | 194.17M | 171.58M |
| Cash flow statement | ||
| Operating cash flow | -$18.54M | -$9.50M |
| Capital expenditure | $3.66M | $661,479 |
| Free cash flow | -$22.20M | -$10.16M |
| Investing cash flow | -$3.66M | -$661,479 |
| Financing cash flow | $26.17M | $9.43M |
| Depreciation & amortization | $1.08M | $436,005 |
| Stock-based compensation | $8.13M | $14.34M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.